FindMyKOL
Clinical trialNCT03292926CompletedPhase 4Interventional

A Novel Analgesia Technique for ACL Reconstruction

NCT03292926 is a phase 4 interventional trial sponsored by Hospital for Special Surgery, New York. As of 18 Nov 2026, it is completed. It studies Bupivacaine and Dexamethasone in Anterior Cruciate Ligament Injury. The registry lists an enrollment of 78 participants at 1 site in 1 country. The registry lists a start date of 4 Oct 2017 and a primary completion date of 6 Mar 2020.

SponsorHospital for Special Surgery, New YorkEnrollment78Anterior Cruciate Ligament Injury
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT03292926
FieldValue
Registry IDNCT03292926
StatusCompleted
PhasePhase 4
Study typeInterventional trial
Lead sponsorHospital for Special Surgery, New York
Enrollment78
Registered sites1
Countries1
ConditionsAnterior Cruciate Ligament Injury
DrugsBupivacaine and Dexamethasone
Start4 Oct 2017
Primary completion6 Mar 2020
Study completion16 Apr 2020
Last update posted19 Sept 2024

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

A comparison of two anesthetic techniques-- the Adductor Canal Block (ACB) and the Adductor Canal Block with Infiltration of the interspace between the popliteal artery and the capsule of the posterior knee (ACB/IPACK)-- in patients undergoing bone-tendon-bone (BTB) anterior cruciate ligament (ACL) reconstruction.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

New York, United States1 site
  • Hospital for Special Surgery

    New York

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew York: 1 siteNY1MassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT03292926

Each answer restates registry values shown on this page.

What is NCT03292926?

NCT03292926 is a phase 4 interventional trial sponsored by Hospital for Special Surgery, New York. It studies Bupivacaine and Dexamethasone in Anterior Cruciate Ligament Injury.

Who leads NCT03292926?

The registry names Jonathan Beathe, MD (principal investigator, Hospital for Special Surgery, New York) as the overall official.

Where does NCT03292926 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT03292926 study?

The registered drug and biological interventions are Bupivacaine and Dexamethasone.

When did NCT03292926 end?

The registry lists a primary completion date of 6 Mar 2020 and a study completion date of 16 Apr 2020. The sponsor last updated the record on 19 Sept 2024.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.